Effectiveness and response predictors of omalizumab in a severe allergic asthma population with a high prevalence of comorbidities: the Australian Xolair Registry.
Australian patients with severe allergic asthma report a high disease burden and have extensive comorbidity. Symptomatic response to omalizumab was high despite significant comorbid disease. Omalizumab is an effective targeted therapy for severe allergic asthma with comorbidity in a real-life setting.
Real-life effectiveness of omalizumab in severe allergic asthma above the recommended dosing range criteria.
Patients with severe allergic asthma above recommended dosing criteria for omalizumab have significantly improved symptom control, quality of life and lung function to a similar degree to within-range participants, achieved without dose escalation above 750 mg.
Decision making and algorithm for the management of pleural effusions.
Pleural effusions can be catagorised in to transudative effusions or exudative effusions. Causes include cardiovascular disease, infection and neoplasm. Diagnosis is the key to determining what management is required. History and examination can elicit the cause of the effusion and radiological investigations can be a useful adjunct. Thoracocentesis and laboratory testing of the pleural fluid is usually diagnostic and can direct further investigations or treatment. Management of the pleural effusion ultimately varies according to the diagnosis but can be either directed towards reversing the cause of the effusion or treating the symptoms that arise as a result of the effusion.
Ambulatory oximetry fails to predict survival in chronic obstructive pulmonary disease with mild-to-moderate hypoxaemia.
Neither resting P(a) O(2) nor proportion of ambulatory oximetry below 90% saturation effectively predicted survival in COPD
Models Of Care For Acute Non-Invasive Ventilation In COPD- Comparison Of Three Tertiary Centres (ACT3 Study)
Managing asthma when inhalers and steroids are not sufficient
How to treat allergic and severe/treatment resistant asthma.
Macrolide therapy for recurrent COPD Exacerbations
A patient has been referred by his GP for specialist assessment and management. He presents with a 12-month history of recurrent, culture-positive, infective exacerbations of COPD.
Take a deep breath
A 46-year-old executive presents with poorly controlled asthma. She has never smoked and does not recall any occupational exposure to allergens
Out of breath
A woman experiences persistent breathlessness, cough and chills that won’t resolve with antibiotic treatment.
A 56-year-old non-smoker, was referred to our respiratory clinic for assessment of a persistent dry cough and shortness of breath…
When is flu not flu?
An otherwise fit and healthy physiotherapy student presents with symptoms that seem like pneumoniaa.